medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2018, Number 1

<< Back

Rev Biomed 2018; 29 (1)

Recurrent pregnancy loss and idiopatic pulmonary hypertension

Vázquez-Tirado A, Medina-Paz L, Vázquez-López S, Che-Morales JL, Cortés-Télles A

Language: Spanish
References: 15
Page: 25-29
PDF size: 444.24 Kb.


ABSTRACT

Recurrent pregnancy loss occurs whenever a woman has 2 or more miscarriages of their clinical pregnancy before 20 weeks of gestation. There are multiple risk factors relates to this condition, among, them, the presence of pulmonary hypertension (PH) is linked with high mortality (30-56% of cases) and risk of miscarriages between 9 weeks and 12 of gestation. The prevalence of both conditions are not well known. Here, we present the case of a 31 year-old women who was admitted to the hospital with an abortion in evolution, immediately after the curettage, the patient exhibit severe hypoxemia in association with Right Heart Failure; the medical approach established that the primary cause of recurrent abortions was an uncontrolled idiopathic pulmonary hypertension.


REFERENCES

  1. Marquard K, Westphal LM, Milki AA, Lathi RB. Etiology of recurrent pregnancy loss in women over the age of 35 years. Fertil Steril. 2010 Sep; 94(4):1473-77.

  2. Ford HB, Schust DJ. Recurrent Pregnancy Loss: Etiology, Diagnosis and therapy. Rev Obstet Gynecol. 2009 Spring; 2(2): 76-83.

  3. Grunig E, Weissmann S, Ehlken N, Fijalkowska A, Fischer C, Fourme T, et al. Stress Doppler echocardiography in relatives of patients with idiopathic and familial pulmonary arterial hypertension: results of a multicenter European analysis of pulmonary artery pressure response to exercise and hypoxia. Circulation 2009 Apr; 119(13): 1747-57.

  4. Simonneau G, Robbins IM, Beqhetti M, Channick RN, Delcroix M, Denton CP, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009 Jun; 54(1 Suppl): S43-54.

  5. Mocumbi AO, Thienemann F, Sliwa K. A global perspective on the epidemiology of pulmonary hypertension. Can J Cardiol. 2015 Apr; 31(4): 375-81.

  6. Galič N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lun Transplantation (ISHLT) Eur Respir J. 2015 Oct; 46(4): 903-75.

  7. Galič N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013 Dec; 62(25 Suppl): D60-72.

  8. Rubin LJ, Badesch DB, Barst RJ, Galič N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 Mar; 346(12): 896- 903.

  9. Cervera R, Font J, Gomez-Puerta JA, Espinosa G, Cucho M, Bucciarelli S, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005 Aug; 64(8): 1205-9.

  10. Ghofrani HA, Galič N, Grimminger F, Grüning E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013 Jul; 369(4): 330-40.

  11. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid síndrome. J Thromb Haemost. 2006 Feb; 4(2): 295-306.

  12. Weiss BM, Zemp L, Seifert B, Hess OM. Outcome of pulmonary vascular disease in pregnancy: A systematic overview from 1978 through 1996. J Am Coll Cardiol. 1998 Jun; 31(7): 1650-7.

  13. Jaďs X, Olsson KM, Barbera JA, Blanco I, Torbicki A, Peacock A, et al. Pregnancy outcomes in pulmonary arterial hypertension in the modern management era. Eur Respir J. 2012 Oct; 40(4): 881-5.

  14. Razo-Morales D. Síndrome antifosfolípidos y anticoagulante lúpico, anticuerpos antifosfolípidos. Rev Mex Patol Clin. 2000 Jul-Sept; 47(3): 168-71.

  15. Loizou S, Singh S, Wypkema E, Asherson RA. Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis. 2003 Nov; 62(11): 1106-11.




2020     |     www.medigraphic.com